Share Name Share Symbol Market Type Share ISIN Share Description
Valirx LSE:VAL London Ordinary Share GB00BWWYSP41 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 5.50p 5.25p 5.75p - - - 0 06:30:08
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -5.8 -8.5 - 14.49

Valirx (VAL) Latest News (1)

More Valirx News
Valirx Takeover Rumours

Valirx (VAL) Share Charts

1 Year Valirx Chart

1 Year Valirx Chart

1 Month Valirx Chart

1 Month Valirx Chart

Intraday Valirx Chart

Intraday Valirx Chart

Valirx (VAL) Discussions and Chat

Valirx Forums and Chat

Date Time Title Posts
18/12/201707:09Valirx 18th May 2015 and Beyond7,742
14/12/201716:18RAINMAKER'S VALUE THREAD8,214
12/12/201715:43ValiRx PLC - A Rough Diamond.6,133
12/12/201715:43*** VALUE INVESTING BOOKS *** 4

Add a New Thread

Valirx (VAL) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Valirx trades in real-time

Valirx (VAL) Top Chat Posts

Valirx Daily Update: Valirx is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker VAL. The last closing price for Valirx was 5p.
Valirx has a 4 week average price of 0.93p and a 12 week average price of 0.93p.
The 1 year high share price is 7.73p while the 1 year low share price is currently 0.93p.
There are currently 263,405,413 shares in issue and the average daily traded volume is 101,832,337 shares. The market capitalisation of Valirx is £14,487,297.72.
cyclades: Partnership deals close Given the clinical progress made in VAL401 and the company’s approach to out-licensing, we believe that ValiRx should be close to agreeing a deal with potential commercial partners in the form of big pharma companies. This has been strongly hinted at in the latest RNS, with ValiRx commenting, “The Company is in discussion with a number of large pharmaceutical companies who are looking to fill their pipelines in this therapeutic area.” To illustrate the potential value here, many historic deals signed by smaller players with big pharma companies for early development stage therapeutic candidates have run into the many hundreds of millions of dollars, representing many multiples of ValiRx’s current market cap. To give just one deal example, in May 2011 Swiss biopharma company Molecular Partners entered into a licence agreement with US pharma giant Allergan for the exclusive global rights to MP0112, a Phase II proprietary therapeutic protein under investigation for the treatment of retinal diseases. The agreement detailed an up-front payment of $45 million and further potential milestone payments of up to $375 million, along with tiered double-digit royalties on any future sales. Of course, the main risk with drug development companies is that therapeutic candidates fail clinical trials. However, we believe that these are reduced somewhat with ValiRx as the active ingredient of VAL401 has a long history of safety, with VAL201 having a consistent safety record to date. Looking ahead, in the coming weeks and months we expect further updates on data analysis from the VAL401 study, along with key initial data from the VAL201 trial. Investors will also be hoping for news of a partnership agreement for VAL401, an event which more than likely will be a major share price appreciation catalyst.
h2owater: ValiRx shares yo-yo on fundraising and pipeline update by Phil Taylor | Dec 1, 2017 9:07am Chairman Oliver de Giorgio-Miller says ValiRx has made big progress in the last 6 months. ValiRx is approaching a pivotal point in its development as it waits for clinical results from two lead programs that it hopes will net it a development partner. The U.K.-based biotech—which has just raised £1 million (around $1.3 million) in a fundraising round—expects to disclose phase 1/2 data on lead drug VAL201 in prostate cancer later this month, along with midstage data for lung cancer candidate VAL401. News of the fundraising and clinical update sparked a short-lived spike in ValiRx shares on the London AIM, although it was quickly reversed, doing little to counteract what has been a fairly steady decline in the stock over the past year. The new funds will be used for “advancing the clinical trial of VAL201 and for the preclinical progress of other programmes,” said the company in a statement, adding that it believes the share price rise is “a consequence of comments and analysis surrounding the company's developmental pipeline.” VAL201 is a peptide drug, delivered by subcutaneous injection, that is being tested in a single-agent trial in patients with locally advanced or metastatic advanced prostate carcinoma. In September, the company said it had seen signs of clinical activity, including a reduction in the prostate cancer biomarker PSA and disease stabilization, with no serious safety issues in patients treated to that date. Meanwhile, VAL401—being taken forward by ValiRx’ ValiSeek unit—is a repurposed drug, a new formulation of risperidone that has more than two decades of clinical experience as an antipsychotic treatment, and ValiRx hopes to show in the forthcoming trial that it can improve quality of life in patients with advanced lung cancer. Pharmacokinetic data reported in September showed that VAL401 behaved like current formulations of risperidone, which should allow ValiRx to reference earlier trials as prepares for additional studies and—potentially—future marketing applications. It also suggested a dose for future trials of 2mg, which is well within the usual dosing range for risperidone. ValiRx’ nonexecutive chairman Oliver de Giorgio-Miller said at the time that the company has “seen considerable progress across our therapeutic portfolio in the last six months, adding value to the company's assets and bringing us closer to the point where our clinical programmes for VAL201 and VAL401 will deliver meaningful data and will bring the company closer to finding a partner.” hTTp://
thebossman: ValiRx PLC Stmnt re Share Price Movement RNS Number : 35891 ValiRx PLC 18 sept 2018 ValiRx Plc ('ValiRx' or the 'Company') Statement re Share Price Movement The board of ValiRx notes the recent fall in the Company's share price and confirms that it is not aware of any reason that would lead to such a movement.
thebossman: Caut.. 7yrs down the line.. A lifetimes waiting..And my wife is very understanding.. Very easy to buy @1.80p yesterday.. Share Price: 1.775 Bid: 1.75 Ask: 1.80 12 August 2010 Cancer Research Technology (CRT) Cancer Research Technology (link is external) has signed a deal to provide biotech company ValiRx plc (link is external) with the global rights to develop a promising compound to treat hormone-resistant prostate cancer. The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients. Under the terms of the deal, ValiRx has exclusive rights to use the compound to treat, prevent and diagnose cancer and other diseases. Cancer Research Technology - Cancer Research UK's development and commercialisation arm - will receive milestone payments throughout the development and commercialisation of the compound and royalty payments for potential licensed treatments. Currently, prostate cancer is the most common cancer amongst men with 36,000 men being diagnosed and around 10,150 deaths each year in the UK. Of all men with advanced stage prostate cancer, hormone therapy will work for between eight and nine out of every 10. But many men will become resistant to the treatment at some stage. This does not appear to be related to the length of time a man is receiving treatment. Dr Phil L’Huillier, Cancer Research Technology’s director of business management, said: "This partnership demonstrates CRT’s ability to maximise its broad network, having identified and licensed this project from Naples, and then in turn partnered it for further preclinical and clinical development with ValiRx. “We will follow further trials to test its suitability as a new treatment to potentially increase survival from this disease with great interest.” Under the terms of the licence with Cancer Research Technology, ValiRx will be responsible for performing the pre-clinical regulatory development of VAL 201 to prepare the compound for early clinical trials in patients. ValiRx will manage the commercialisation of potential treatments after clinical trials. Satu Vainikka, CEO of ValiRx, said: “This is a significant and exciting opportunity for ValiRx and we look forward to continue working with CRT and in taking VAL 201 forward in its next stage of development as a potentially exciting treatment against prostate cancer.”
galashiels: Can you still afford to ignore what I have said here? Instead of hating each other we should focus on AIM listed problem: If these guys are behind any AIM listed company, people should look at the dilution history of that company, in general they may find dilution - consolidation - dilution pattern, no matter how good the company, if you are going to keep getting diluted to keep a company afloat, what's the point, It's you who are feeding money to them, source of income is shareholders. Cairn Financial Advisers LLP WH Ireland Limited Hybridan LLP Daniel Stewart & Company Plc Northland Capital Partners Do go back and check those penny stocks that you may have been diluted out in the past, were these guys behind those companies too? Feel free to copy this post and post it on any thread that you deem proper to highlight the issue of small investors getting screwed time after time. There are 1000's of patents on cancer, so don't fall for the patent news, what you need is this company making money or raising money that is not off your back. YA Global Master SPV Ltd ("Yorkville") How is your investment panning out, so far? Likely to end-up owning 150,000,000 shares after conversion? In the event that "Yorkville" cancelled their "investment" there would be no more money for the directors to pay themselves. What is the amount of the director''s pay, out of £4m per year cash burn? If you are the type who ramps a stock, you need to make sure that the risk of dilution is minimised, otherwise as soon as the share price were to go up, it would be destroyed by so called "placing". DILUTION DILUTION AND MORE DILUTION. The commissioned and deceptive hype "report" is just the beginning. the companies or funds covered in this research may pay us a fee, commission or other remuneration in order for this research to be made available. Placing history on page 32 is intentionally rigged to paint a deceptive image. hxxp:// i.e Placing @ 750p in May 08? (at a glance it would looks as though the share price just kept going down for no reason.) The real price @6p Disclaimer trick:The number of shares and share prices have been corrected for the 1-for-125 consolidation in April 2015 and the 1-for-30 consolidation in July 2007 Note: not every event is listed in this table The company will require more resources to take VAL201 and VAL401 into further development and to promote VAL301 into a Phase I trial for endometriosis ► Apart from the two institutions, Yorkville and Bracknor, that have acquired small shareholdings through conversion of convertible loan notes, ValiRx does not have any institutional shareholders Funding rounds are likely to get larger If you are investing in here then go back into each and every dilution event and look at the discount levels along with consolidation and re-dilution time frame. 15/05/2015 3,772,151,750 shares were "Reorganised" into 30,177,214 shares. Today 30,177,214 shares have now been diluted into 143,809,744 Question, how long before 3bln shares are in circulation ready to be "RE-ORGANISED" yet again? MOVE ON AND STAY AWAY. You think this company is immune from liquidation? Think again.
galashiels: DILUTION DILUTION AND MORE DILUTION. The commissioned and deceptive hype "report" is just the beginning. the companies or funds covered in this research may pay us a fee, commission or other remuneration in order for this research to be made available. Placing history on page 32 is intentionally rigged to paint a deceptive image. hxxp:// i.e Placing @ 750p in May 08? (at a glance it would looks as though the share price just kept going down for no reason.) The real price @6p Disclaimer trick:The number of shares and share prices have been corrected for the 1-for-125 consolidation in April 2015 and the 1-for-30 consolidation in July 2007 Note: not every event is listed in this table The company will require more resources to take VAL201 and VAL401 into further development and to promote VAL301 into a Phase I trial for endometriosis ► Apart from the two institutions, Yorkville and Bracknor, that have acquired small shareholdings through conversion of convertible loan notes, ValiRx does not have any institutional shareholders Funding rounds are likely to get larger If you are investing in here then go back into each and every dilution event and look at the discount levels along with consolidation and re-dilution time frame.
red rook: bossman, Regarding your first Fact.. 'SP at all time low..'. IMO the BOD are not concerned about the share price (SP). Rather, I believe that their intention will be to maintain, if possible, the market cap (MC) currently around the £2.5M mark, irrespective of where the share price falls to. IMO the following will play out going forward: 1) There will be no game changing news as some are speculating, wrt deals being done, before the AGM. In fact, VAL has indicated they will only complete their clinical trial by the end of the year. No deal can be done before that data is obtained and fully analyzed. 2) I suspect that all the resolutions will be passed. 3) I expect that soon after the AGM the next rounds of share dilution to start. Even JG, one of VAL's stalwarts, expects there is a need for another £3m in funds to cover existing expenses to years end. I would expect the number of shares by years end to be around the 400m mark. For a MC of around £2.5m this would mean a share price of around 0.6p. I do not think that LT shareholders - sorry second hand shareholders - figure in the BOD's equation. IMO, if the BOD can get to years end with a MC of around £2.5m they will be satisfied irrespective of where the share price is. I think that the nominal share price is 0.1p. It would explain why the BOD have not piled in now, even at a share price of 2.5p. JG I do read your posts and I realise that you have a large investment in VAL, but you have called it wrong on so many previous occassions. Please note that this is just MY assessment of the situation. I'm sure I will get a lot of flak for this less than rosy assessment, but I am happy to stick my neck out and see what transpires going forward.
defcon3: AIM-listed ValiRx (VAL) operates in the biotech space, developing cancer drugs. I've been pretty beastly in previous pieces (see HERE) but I am pleased to note that the company has seen fit to address the questions asked over Companies House filings. As pointed out HERE they were indeed wrong and they have now been corrected. Good news. My hope is that the questions over the Bracknor funding deal will now be addressed.We were originally told that up to £4 million could be drawn in tranches of £500,000, which could then be converted into equity at 90% of a volume-weighted average price formula, and that warrants would also be issued alongside conversion shares as portions of the debt were converted, at a rate of 115% of the number of shares issued on conversion.We were not told how the warrant exercise price would be derived, but helpfully the Bracknor website stated that its funding package was for up to £8.6 million, which conveniently worked out that the tranches of warrants would be exercisable at the same price as the issue price of the relevant tranches of conversion shares.But the subsequent announcements of conversions and warrant issues did not match the 115% originally stated, and we left with the very unsatisfactory situation of being told that the terms of the warrant issues had been changed. Now we know neither the number of warrants to be issued, nor the exercise price!As it happens, the Bracknor website still maintains that the maximum funding package is £8.6 million. We have been told that a total of 6,367,663 warrants were issued, exercisable at 9p, pursuant to the conversion of the first £500,000 tranche of convertible loan (out of £4 million).The maths works out (within rounding errors) that if the share price does not move whilst ValiRx draws down the rest of its cash under the Bracknor deal, and Bracknor converts all of the debt then £4.6 million would indeed be raised from the exercise of the warrants issued.This is all very well, but I cannot see from what has been announced how the number or the exercise price of the warrants is calculated. As such, despite having a sympathetic approach to companies developing cancer therapies, I cannot get as far as assessing any value here: I simply don't know how much I might be diluted by.That, and the small matter of shareholder authorities for the issuance of shares and rights to subscribe for or to convert any securities into shares granted at the last AGM which have now been heavily utilised to the point where I can't see how the company has the authority to draw even a second tranche of the funding deal (let alone all of the remaining seven) without seeking a big increase at the next AGM leaves me unable to get down to trying to assess whether to bung a few quid into this fine enterprise. Perhaps now that the Companies House filings have been sorted out we'll get an update on that, as well as how the warrant terms are now calculated. I really do hope so, as this is just the sort of investment I would like to consider: the opportunity to take a small stake in something which benefits society as well as offering a decent return is very attractive to me. But until I have some idea of what I might end up owning I can't make that step.With on-going clinical trials the company has bills to pay and one can fully appreciate the desire for a funding package to be in place – even if the company is simply using it as a kind of insurance policy to fall back on if other funding or corporate deals fail to materialise as hoped. It would be wrong to put the clinical trials at risk, given the effect on the patients involved.I have previously pointed to a bit of a problem in the shareholder authorities currently in place, which allows the board to issue more confetti. At the last count there were 49,218,931 shares in issue, and a further 6,367,663 warrants to subscribe at 9p had been handed to Bracknor. That makes a total of 55,586,594 shares and warrants.As I understand it the authorities currently in place allow the company to go up to a little over 60 million shares and/or agreements to allot shares or grant rights to subscribe or to convert any security into shares. So my understanding is that headroom now available amounts to another 5 million shares or rights etc. That is, of course, a long way short of the number of shares and warrants issued as the result of the full conversion of the first £500,000 of the Bracknor package and so I rather doubt that there can be any further drawdown until a new shareholder authority is in place.Against that we have an AGM coming up – last year it was held on 15 May, after the FY14 results had been released on 16 April. One might imagine, then, that results are imminent. It will be interesting to see what proposals are put to shareholders with regard to future share issuance. By my maths, if the share price remains where it has been through the drawdown and conversion of the first tranche of Bracknor funding, we are looking at a further 44.5 million warrants being issued alongside around another 46 million shares. That is quite some dilution – and my fear is that it could be worse as Bracknor will no doubt be selling its conversion shares as well as any shares issued from the exercise of warrants.Why do I assume this? Well the first £500,000 tranche saw Bracknor issued with a total of 6.7 million conversion shares. Had Bracknor held on to those shares it would now hold 13.6% of the issued equity which would have seen a few TR-1s flying around. There have been none so I assume that Bracknor has dumped in smart fashion – which suggests that this will continue if/when any further tranches of funding are drawn by the company.Whilst it is to be noted that the share price has been fairly stable through the (now complete) conversion of tranche 1, I would be less than certain that this will be the case going forward with the other (up to) seven: the nature of death spiral funding tends to place heavy downward pressure on the share price. There is the obvious risk that a falling share price will mean that the conversion price falls and thus the number of conversion shares which need to be issued rises substantially.Of course, if some corporate deal comes along then one assumes that the remaining Bracknor facility will not be needed. I guess that's the investment risk.I'd like some clarity over those warrants before considering an investment, and I'll wait for the AGM notice to see what is proposed with regard to authorities sought by the board for the issue of further shares. If that is limited and the warrant issue is cleared up I'll take a closer look t- See more at:
thebossman: Every day you can Learn something new about investing... By Ken Little Why is a stock that cost $50 less than another stock priced at $10? This question opens a point that often trips up beginning investors: The per-share price of a stock is thought to convey some sense of value relative to other stocks. Nothing could be farther from the truth. In fact, except for its use in some calculations, the per-share price is virtually meaningless to investors doing fundamental analysis. If you follow the technical analysis route to stock selection, it’s a different story, but for now let’s stick with fundamental analysis. The reason we aren’t concerned with per-share price is that it is always changing and, since each company has a different number of outstanding shares, it doesn’t give us a clue to the value of the company. For that number, we need the market capitalization or market cap number. The market cap is found by multiplying the per-share price times the total number of outstanding shares. This number gives you the total value of the company or stated another way, what it would cost to buy the whole company on the open market. Here’s an example: Stock price: $50 Outstanding shares: 50 million Market cap: $50 x 50,000,000 = $2.5 billion To prove our opening sentence, look at this second example: Stock price: $10 Outstanding shares: 300 million Market cap: $10 x 300,000,000 = $3 billion This is how you should look at these two companies for evaluation purposes. Their per-share prices tell you nothing by themselves. What does market cap tell you? First, it gives you a starting place for evaluation. When looking a stock, it should always be in a context. How does the company compare to others of a similar size in the same industry? The market generally classifies stocks into three categories: Small Cap under $1 billion Mid Cap $1 - $10 billion Large Cap $10 billion plus Some analysts use different numbers and others add micro caps and mega caps, however the important point is to understand the value of comparing companies of similar size during your evaluation. You will also use market cap in your screens when looking for a certain size company to balance your portfolio. Conclusion Don’t get hung up on the per-share price of a stock when making your evaluation. It really doesn’t tell you much. Focus instead on the market cap to get a picture of the company’s value in the market place.
defcon3: On 21 March this year, AIM-listed ValiRx (VAL) announced a convertible loan facility with Bracknor Fund Ltd. It was announced that the company could draw down up to £4 million in tranches of £500,000. But it seems that some of the information given was either wrong or just missing, not to mention a small problem of share issuance authorities which look to be insufficient to seal the deal. Having had no reply to two emails sent to the company, I am assuming that the conclusions I have come to are correct. It is not pretty.Firstly there is the small matter of just how much has been raised. ValiRx says up to £4 million. But looking at the Bracknor website, I see that Bracknor thinks it will fork out up to £8.6 million. This is, perhaps explained by the issuance of warrants as part of the package – but even that is mired in confusion and missing information.Firstly, the company's 21 Mar RNS does not say at what price the warrants are exercisable. This had me getting out the calculator: what we were told is that the number of warrants to be issued as part of the tranches of loan conversion would amount to 115% of the number of loan conversion shares issued. If we do the maths (215% of £4 million = £8.6 million) then it seems that these conversion warrants are to be exercisable at the same price the shares issued in the associated loan conversion – which is calculated as being 90% of a volume weighted average price formula.Of course, that does not mean that there might exist an alternative mechanism which could be even worse – see Cynical Bear's excellent demolition of the deal between Vast Resources and Crede (HERE). The company has not indicated that this might be the case – but since it has not bothered to give full details of its package with Bracknor one is inclined to consider all possibilities.We are told that:The Company has agreed to issue CLN Warrants such that, at the point of any conversion of CLNs ("Conversion"), the Company shall issue CLN Warrants to Bracknor at a rate of 115% of the number of shares to be issued pursuant to the corresponding Conversion. The CLN Warrants shall be exercisable at any time prior to the fifth anniversary of the date of their issue.This brings us to yesterday's RNS which announced that the first tranche of £500,000 loan notes had been issued, and Bracknor had applied to convert the first £90,000 of them: 1,184,211 shares are to be issued as a result – which works out at 7.6p per share. So we might expect an issue of warrants over 115% of 1,184,211 shares = 1,361,842 warrants.But what we are told is that: Pursuant to the Bracknor agreement the Company has also issued Bracknor with a warrant over 4,926,741 ordinary shares in the Company, which may be exercised at a price of 9 pence per share at any time until the fifth anniversary of issue, being 31 March 2021.Er....that's not 115%, is it?!Let us go back to the 21 Mar RNS:As part of the agreement, the Company has agreed to issue warrants to Bracknor ("CLN Warrants"). Further details of the CLNs and the CLN Warrants are set out below.Aha – are there "Warrants" and "CLN Warrants", then? Why were there no details the "Warrants" given in that RNS?And are we to expect a further RNS at some point detailing the issue of another 1,361,842 "CLN Warrants" as a result of the conversion of £90,000 of CULs?Why has ValiRx not been clear about all this? I suggest that "CLN Warrants" will indeed be issued, exercisable at 7.6p. The 9p exercise price of the "Warrants" looks to be a bit of a red herring, given that the share price is sitting at 8.125p mid. The death spiral effect of the funding package looks to me to be set to have only one effect on the share price – and it is not an upward movement!I think ValiRx has not given enough detail about this Bracknor funding package and it needs to come clean.Now let us consider the effect of the package as a whole. If we (extremely generously) assume that the share price is not forced lower by the death spiral effect, and assume that the whole loan ends up being converted at 7.6p, we will see 52.6 million shares being issued as a result. Add in the "CUL Warrants": 115% of 52.6 million = 60.5 million. That's a total of 113.1 million shares, once the warrants have been exercised.But at the last AGM there were (after a capital reorganisation) about 31 million shares in issue, and the board was given authority to issue a further (approx.) 31 million shares. Since then we have seen about 12 million shares issued in a placing and a funding package with YA Global. That leaves authority for the issue of about another 19 million shares.Yet ValiRx has just handed out about 1.2 million shares, 4.9 million "Warrants" and looks to me to be set to dish out a further 1.4 million "CUL Warrants".It rather looks to me as though the company is going to need a very substantial increase in the number of shares it is allowed to issue when it comes to the next AGM.Will the turkeys vote for Christmas? Have shareholders realised that even on an unchanged share price they are set to be diluted by 118 million shares under this deal with Bracknor?One might also consider the implications of Rule 9 of the Takeover Code. Bracknor, one assumes, will not want to go over 30% of the company for fear of triggering a mandatory bid. But with all those shares heading its way, there is a simple solution to that little problem.....Sell!- See more at:
Valirx share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20171218 07:13:33